The trumenba market research report is one of a series of new reports that provides trumenba market statistics, including the trumenba industry global market size, regional shares, competitors with the trumenba market share, detailed trumenba market segments, market trends, and opportunities, and any further data you may need to thrive in the trumenba industry. This trumenba market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The growth in the forecast period can be attributed to growing levels of vaccination coverage, rising focus on preventive healthcare, rising burden of chronic diseases, expansion of healthcare infrastructure, and increasing immunization programs. Major trends in the forecast period include advancements in vaccine technology, development of new vaccine formulations, advancements in immunization strategies, advancements in dosing schedules, and technological advancements in vaccine delivery.
The increasing incidence of meningococcal disease is expected to drive the growth of the Trumenba market. Meningococcal disease is caused by Neisseria meningitidis, a bacterium responsible for severe conditions such as meningitis and bloodstream infections. Factors such as bacterial transmission, environmental influences, and insufficient vaccination coverage contribute to the rising cases of meningococcal infections, leading to greater investments in preventive measures and healthcare infrastructure worldwide. Trumenba helps reduce the risk of invasive meningococcal diseases, including meningitis and bloodstream infections, by providing immunity against the Neisseria meningitidis serogroup B. For example, the Meningococcal Reference Unit (MRU) reported in August 2024 that there were 396 cases of invasive meningococcal disease in the UK during the 2022-2023 period, compared to 205 cases in the previous year. This increase in cases is expected to further stimulate demand for Trumenba.
The expansion of vaccination coverage is also contributing to the growth of the Trumenba market. Vaccination involves administering a vaccine to stimulate the immune system and protect against specific diseases. Increased access to vaccines, public awareness efforts, and improvements in healthcare systems have led to higher immunization rates and more effective disease prevention. Trumenba plays an important role by providing targeted protection against Neisseria meningitidis serogroup B, reducing the risk of invasive meningococcal diseases, and enhancing vaccination coverage for individuals at higher risk. A report from the World Health Organization in July 2024 indicated that 37 countries adopted a one-dose HPV vaccination schedule in 2023, reaching over 45% of girls aged 9-14. Furthermore, global first-dose HPV vaccine coverage for girls increased from 20% in 2022 to 27% in 2023, moving closer to the target of 90% by 2030. This growth in vaccination coverage is expected to further drive the demand for Trumenba.
The significant trend in the Trumenba market is the development of combination vaccines, such as pentavalent meningococcal vaccines, which aim to enhance immunization coverage and offer protection against multiple serogroups of Neisseria meningitidis. A pentavalent vaccine protects against five different serogroups: A, C, W, Y, and B, providing broader immunity against meningococcal infections. For example, in October 2023, Pfizer received FDA approval for PENBRAYA, a novel pentavalent meningococcal vaccine. This combination vaccine, which merges Trumenba and Nimenrix, is the first of its kind to offer protection against five major meningococcal serogroups, which are responsible for the majority of invasive meningococcal diseases worldwide. PENBRAYA is aimed at adolescents and young adults aged 10 to 25 and strengthens Pfizer's vaccine portfolio by providing enhanced protection against a potentially deadly disease.
The key company operating in the trumenba market is Pfizer Inc.
North America was the largest region in the trumenba market in 2024. The regions covered in trumenba report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the trumenba market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Trumenba is a vaccine designed to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroup B. As a recombinant meningococcal group B vaccine, it stimulates the immune system to produce antibodies against serogroup B bacteria, offering protection against serious infections such as meningitis and bloodstream infections.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The primary clinical indications for Trumenba include meningococcal disease prevention, vaccination for high-risk populations, adolescents and young adults, and post-exposure vaccination. Meningococcal disease prevention involves strategies to reduce the risk of infection from Neisseria meningitidis, including vaccination, early detection, and the administration of prompt antibiotic treatment. Trumenba is distributed through various channels such as hospitals, clinics, retail pharmacies, and specialty pharmacies, serving a wide range of end users, including hospitals, clinics, research institutes, ambulatory surgical centers, and others.
The trumenba market consists of sales of monovalent, combination vaccines, the trumenba 2-dose regimen, booster doses, and nimenrix. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The growth in the forecast period can be attributed to growing levels of vaccination coverage, rising focus on preventive healthcare, rising burden of chronic diseases, expansion of healthcare infrastructure, and increasing immunization programs. Major trends in the forecast period include advancements in vaccine technology, development of new vaccine formulations, advancements in immunization strategies, advancements in dosing schedules, and technological advancements in vaccine delivery.
The increasing incidence of meningococcal disease is expected to drive the growth of the Trumenba market. Meningococcal disease is caused by Neisseria meningitidis, a bacterium responsible for severe conditions such as meningitis and bloodstream infections. Factors such as bacterial transmission, environmental influences, and insufficient vaccination coverage contribute to the rising cases of meningococcal infections, leading to greater investments in preventive measures and healthcare infrastructure worldwide. Trumenba helps reduce the risk of invasive meningococcal diseases, including meningitis and bloodstream infections, by providing immunity against the Neisseria meningitidis serogroup B. For example, the Meningococcal Reference Unit (MRU) reported in August 2024 that there were 396 cases of invasive meningococcal disease in the UK during the 2022-2023 period, compared to 205 cases in the previous year. This increase in cases is expected to further stimulate demand for Trumenba.
The expansion of vaccination coverage is also contributing to the growth of the Trumenba market. Vaccination involves administering a vaccine to stimulate the immune system and protect against specific diseases. Increased access to vaccines, public awareness efforts, and improvements in healthcare systems have led to higher immunization rates and more effective disease prevention. Trumenba plays an important role by providing targeted protection against Neisseria meningitidis serogroup B, reducing the risk of invasive meningococcal diseases, and enhancing vaccination coverage for individuals at higher risk. A report from the World Health Organization in July 2024 indicated that 37 countries adopted a one-dose HPV vaccination schedule in 2023, reaching over 45% of girls aged 9-14. Furthermore, global first-dose HPV vaccine coverage for girls increased from 20% in 2022 to 27% in 2023, moving closer to the target of 90% by 2030. This growth in vaccination coverage is expected to further drive the demand for Trumenba.
The significant trend in the Trumenba market is the development of combination vaccines, such as pentavalent meningococcal vaccines, which aim to enhance immunization coverage and offer protection against multiple serogroups of Neisseria meningitidis. A pentavalent vaccine protects against five different serogroups: A, C, W, Y, and B, providing broader immunity against meningococcal infections. For example, in October 2023, Pfizer received FDA approval for PENBRAYA, a novel pentavalent meningococcal vaccine. This combination vaccine, which merges Trumenba and Nimenrix, is the first of its kind to offer protection against five major meningococcal serogroups, which are responsible for the majority of invasive meningococcal diseases worldwide. PENBRAYA is aimed at adolescents and young adults aged 10 to 25 and strengthens Pfizer's vaccine portfolio by providing enhanced protection against a potentially deadly disease.
The key company operating in the trumenba market is Pfizer Inc.
North America was the largest region in the trumenba market in 2024. The regions covered in trumenba report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the trumenba market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Trumenba is a vaccine designed to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroup B. As a recombinant meningococcal group B vaccine, it stimulates the immune system to produce antibodies against serogroup B bacteria, offering protection against serious infections such as meningitis and bloodstream infections.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The primary clinical indications for Trumenba include meningococcal disease prevention, vaccination for high-risk populations, adolescents and young adults, and post-exposure vaccination. Meningococcal disease prevention involves strategies to reduce the risk of infection from Neisseria meningitidis, including vaccination, early detection, and the administration of prompt antibiotic treatment. Trumenba is distributed through various channels such as hospitals, clinics, retail pharmacies, and specialty pharmacies, serving a wide range of end users, including hospitals, clinics, research institutes, ambulatory surgical centers, and others.
The trumenba market consists of sales of monovalent, combination vaccines, the trumenba 2-dose regimen, booster doses, and nimenrix. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Trumenba Market Characteristics4. Trumenba Market Trends And Strategies5. Trumenba Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market7. Global Trumenba Pricing Analysis & Forecasts30. Global Trumenba Market Competitive Benchmarking And Dashboard31. Key Mergers And Acquisitions In The Trumenba Market32. Recent Developments In The Trumenba Market
3. Trumenba Market Biologic Drug Characteristics
6. Global Trumenba Growth Analysis And Strategic Analysis Framework
8. Trumenba Market Segmentation
9. Global Trumenba Epidemiology Of Clinical Indications
10. Trumenba Market Regional And Country Analysis
11. Asia-Pacific Trumenba Market
12. China Trumenba Market
13. India Trumenba Market
14. Japan Trumenba Market
15. Australia Trumenba Market
16. South Korea Trumenba Market
17. Western Europe Trumenba Market
18. UK Trumenba Market
19. Germany Trumenba Market
20. France Trumenba Market
21. Eastern Europe Trumenba Market
22. North America Trumenba Market
23. USA Trumenba Market
24. Canada Trumenba Market
25. South America Trumenba Market
26. Middle East Trumenba Market
27. Africa Trumenba Market
28. Trumenba Market Competitive Landscape And Company Profiles
29. Global Trumenba Market Pipeline Analysis
33. Trumenba Market High Potential Countries, Segments and Strategies
34. Appendix
Executive Summary
Trumenba Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on trumenba market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for trumenba ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The trumenba market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Clinical Indication: Meningococcal Disease Prevention; High-Risk Populations; Adolescents And Young Adults; Post-Exposure Vaccination2) By Distribution Channel: Hospital And Clinics; Retail Pharmacies; Specialty Pharmacies
3) By End-User: Hospitals; Clinics; Research Institutes; Ambulatory Surgical Centers; Other End-Users
Key Companies Profiled: Pfizer Inc.
Countries: Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- Pfizer Inc.
